Clinical Trials
25
10 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
7
28.0%
Completed
5
20.0%
Not yet recruiting
3
12.0%
Recruiting
8
32.0%
Withdrawn
2
8.0%
No approval data available
- Associate Professor Ines Pires da Silva and her team have expanded one of the world's largest melanoma immunotherapy research cohorts to more than 600 patients, with paired pre- and post-treatment tumour samples. - A new online clinical tool launching this month will predict an individual patient's risk of melanoma recurrence following surgery, using clinical features to generate personalised risk estimates. - The research program focuses on identifying biomarkers that predict immunotherapy response and resistance, with discoveries that could influence treatment across multiple tumour types beyond melanoma. - The team has published nearly 10 scientific papers in the past year and anticipates major publications in 2026 and 2027, with Assoc Prof Pires da Silva taking on leadership roles at ASCO and ESMO.
- Scientists at the Garvan Institute have captured the first-ever real-time video of CD169-positive macrophages attacking and engulfing live melanoma cells using intravital two-photon microscopy. - The study reveals that these macrophages suppress melanoma growth independently of T cells and B cells, challenging the conventional understanding of anti-tumor immunity. - CD169-positive macrophages were also identified in human melanoma tissue samples, concentrated around tumor edges, confirming translational relevance. - The findings point to a potential new therapeutic strategy for "cold tumors" that fail to respond to current immunotherapies, by harnessing or boosting this macrophage population.
- Professor Richard Scolyer, co-director of Melanoma Institute Australia and 2024 Australian of the Year, has died at age 59 after a courageous battle with glioblastoma. - Scolyer became the first brain cancer patient worldwide to receive combination immunotherapy before surgery, an approach he and Professor Georgina Long pioneered for advanced melanoma. - The experimental treatment extended his life beyond initial expectations, and encouraging findings have triggered an early-stage clinical trial in the United States. - His research with Long transformed advanced melanoma from a near-certain death sentence to a disease where half of patients are now essentially cured, up from less than 10%.
- The phase 3 EORTC-2139-MG/Columbus-AD trial demonstrated that adjuvant encorafenib plus binimetinib improved 12-month recurrence-free survival to 86% versus 70% with placebo in patients with stage IIB/C BRAF V600-mutant melanoma. - The combination therapy was generally well tolerated with a manageable safety profile, though 33% of patients discontinued treatment due to adverse events. - This represents the first randomized adjuvant trial of BRAF-directed therapy in stage IIB/IIC melanoma, potentially offering patients an alternative to immunotherapy in the adjuvant setting.
- Strand Therapeutics announced preliminary Phase 1 data for STX-001, a self-replicating mRNA therapy encoding IL-12, showing favorable safety and encouraging anti-tumor activity in 22 patients with checkpoint inhibitor-refractory solid tumors. - The trial demonstrated multiple RECIST responses including a confirmed complete response and partial responses, with systemic immune activation observed even in non-injected lesions across multiple tumor types. - STX-001 was well-tolerated up to 300 µg with dose-dependent increases in plasma IL-12 and IFN-γ, representing the first clinical validation of Strand's programmable mRNA platform technology. - The company plans to advance to Phase 2 monotherapy trials and initiate combination studies with checkpoint inhibitors, while developing STX-003, an intravenous version, for 2026 patient dosing.
- A groundbreaking experimental treatment combining three checkpoint inhibitor immunotherapies before surgery has shown promising results in glioblastoma, with one patient remaining cancer-free for over 18 months. - The innovative approach, developed by Professor Georgina Long AO, demonstrated increased immune cell activation and diversity in the treated tumor, suggesting an enhanced immune response against cancer cells. - An Australian-led international clinical trial is being planned to evaluate double immunotherapy, with some patients receiving additional chemotherapy, to validate this potential breakthrough in glioblastoma treatment.
- Australian clinical trial demonstrates unprecedented 51% survival rate at seven years for melanoma patients with brain metastases using combination immunotherapy with nivolumab and ipilimumab. - The groundbreaking study, led by Melanoma Institute Australia, transforms the prognosis for advanced melanoma patients, extending survival from traditional 16 weeks to potential cure. - Research team confirms long-term disease control achievement, recommending combination immunotherapy as the new standard of care for melanoma brain metastasis patients.
- Updated data from the NADINA trial demonstrates that neoadjuvant ipilimumab plus nivolumab significantly improves event-free and distant metastasis-free survival compared to adjuvant nivolumab in resectable stage III melanoma. - An updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) confirms the long-term benefits of neoadjuvant immunotherapy, particularly with combination checkpoint inhibition. - Major pathologic response (MPR) is identified as a strong prognostic marker, with patients achieving MPR showing significantly improved recurrence-free survival rates. - Neoadjuvant BRAF/MEK targeted therapy is shown to be less effective than neoadjuvant immunotherapy and equivalent to adjuvant BRAF/MEK therapy.
- Professor Richard Scolyer, diagnosed with terminal stage 4 glioblastoma in 2023, remains cancer-free one year after receiving a first-of-its-kind immunotherapy treatment he helped develop. - The groundbreaking approach combined immunotherapy drugs administered before and after surgery, along with the world's first personalized vaccine tailored to his tumor's characteristics. - Despite initial complications including seizures, liver issues, and pneumonia, Scolyer has returned to his daily routine, though researchers caution that while promising, the treatment requires further study in larger patient populations.
